Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The virological efficacy will be no different in children treated with single versus double boosted PI second line ART regimens.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
• Collaborator: Ministry of Education, Thailand
• Treatments: HIV Protease Inhibitors; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir

Criteria

Inclusion Criteria:

1. Children (< 18 years old) with HIV infection

2. Have failed NNRTI-based ART

3. Received second-line regimen with either one or two boosted PIs (Note: low dose ritonavir to boost the other PI will not be count as additional PI)

4. Began ritonavir-boosted PI prior to June 30, 2007

Exclusion Criteria:

1. Have previously received PI treatment for longer than 30 days prior to the current PI regimen.

2. Has previously or currently been treated with abacavir or tenofovir

3. Currently on ART other than NRTI, NNRTI and PI drug classes